The DOI matches its Crossref record.
Cytokine Therapy With Interleukin-2/Anti–Interleukin-2 Monoclonal Antibody Complexes Expands CD4+CD25+Foxp3+ Regulatory T Cells and Attenuates Development and Progression of Atherosclerosis
Open accessAbstract
Background—: CD4+CD25+Foxp3+ regulatory T cells (Tregs) attenuate atherosclerosis, but their therapeutic application by adoptive transfer is limited by the need for their expansion in vitro and limited purity. Recently, an interleukin (IL)-2/anti–IL-2 neutralizing monoclonal antibody (IL-2/anti–IL-2 mAb) complex has been shown to expand these Tregs. We examined the capacity of a modified IL-2/anti–IL-2 mAb treatment to expand Tregs and inhibit both the progression and development of developed atherosclerosis. Methods and Results—: Six-week old apolipoprotein E–deficient mice fed a high-fat diet for 8 weeks were administered IL-2/anti–IL-2 mAb commencing 2 weeks after starting the diet. Tregs in the spleen, lymph node, and liver were selectively expanded without affecting CD4+, CD8+, or natural killer cells. Tregs were increased in lesions and lesion size reduced. CD4+ T-cells, macrophages, mature dendritic cells, proliferating cell nuclear antigen+ cells, and monocyte chemoattractant protein-1 and vascular cell adhesion molecule-1 were reduced. In anti-CD3–stimulated splenocytes, proliferation and secretion of Th1, Th2, and Th17 (IL-17) cytokines and IL-1β were reduced. To determine whether treatment attenuated progression of developed atherosclerosis, 6-week-old apolipoprotein E–deficient mice were fed a high-fat diet for 6 weeks, followed by IL-2/anti–IL-2 mAb treatment for 6 weeks while continuing the high-fat diet. Treatment also increased Tregs without affecting CD4+, CD8+, or natural killer cells, suppressed inflammation, and greatly attenuated progression of atherosclerosis. Conclusions—: IL-2/anti–IL-2 mAb treatment in vivo attenuates atherosclerosis via selective Tregs expansion. The findings suggest that cytokine-based IL-2/anti–IL-2 mAb complex therapy could represent an attractive approach for treating atherosclerosis, because it markedly attenuates progression as well as development, by modulating its immunoinflammatory component.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Immunity and Inflammation in Atherosclerosis
Wolf, D., & Ley, K. (2019) · Circulation Research · doi:10.1161/circresaha.118.313591 · Cited by 1,697
The immunology of atherosclerosis
Gisterå, A., & Hansson, G. K. (2017) · Nature Reviews Nephrology · doi:10.1038/nrneph.2017.51 · Cited by 982
T cell subsets and functions in atherosclerosis
Saigusa, R., Winkels, H., & Ley, K. (2020) · Nature Reviews Cardiology · doi:10.1038/s41569-020-0352-5 · Cited by 721
The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases
Klatzmann, D., & Abbas, A. K. (2015) · Nature Reviews Immunology · doi:10.1038/nri3823 · Cited by 636
Huynh, K., Bernardo, B. C., McMullen, J. R., & Ritchie, R. H. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.01.003 · Cited by 553
Cytokines in atherosclerosis: Key players in all stages of disease and promising therapeutic targets
Ramji, D. P., & Davies, T. S. (2015) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2015.04.003 · Cited by 469
Regulatory T Cells Promote Macrophage Efferocytosis during Inflammation Resolution
Proto, J. D., Doran, A. C., Gusarova, G., Yurdagul, A., Sozen, E., Subramanian, M., Islam, M. N., Rymond, C. C., Du, J., Hook, J., et al. (2018) · Immunity · doi:10.1016/j.immuni.2018.07.015 · Cited by 441
Interleukin-2: Biology, Design and Application
Arenas-Ramirez, N., Woytschak, J., & Boyman, O. (2015) · Trends in Immunology · doi:10.1016/j.it.2015.10.003 · Cited by 359
Inflammation in acute myocardial infarction: the good, the bad and the ugly
Matter, M. A., Paneni, F., Libby, P., Frantz, S., Stähli, B. E., Templin, C., Mengozzi, A., Wang, Y.-J., Kündig, T. M., Räber, L., et al. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehad486 · Cited by 357
Role of Lymphocytes in Myocardial Injury, Healing, and Remodeling After Myocardial Infarction
Hofmann, U., & Frantz, S. (2015) · Circulation Research · doi:10.1161/circresaha.116.304072 · Cited by 296
The Influence of Innate and Adaptive Immune Responses on Atherosclerosis
Witztum, J. L., & Lichtman, A. H. (2014) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-020712-163936 · Cited by 277
Regulatory T Cells License Macrophage Pro-Resolving Functions During Atherosclerosis Regression
Sharma, M., Schlegel, M. P., Afonso, M. S., Brown, E. J., Rahman, K., Weinstock, A., Sansbury, B. E., Corr, E. M., van Solingen, C., Koelwyn, G. J., et al. (2020) · Circulation Research · doi:10.1161/circresaha.119.316461 · Cited by 259
Histone/protein deacetylase 11 targeting promotes Foxp3+ Treg function
Huang, J., Wang, L., Dahiya, S., Beier, U. H., Han, R., Samanta, A., Bergman, J., Sotomayor, E. M., Seto, E., Kozikowski, A. P., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-09211-3 · Cited by 96
Quercetin protects against atherosclerosis by inhibiting dendritic cell activation
Lin, W., Wang, W., Wang, D., & Ling, W. (2017) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201700031 · Cited by 77
Metadata
- Authors
- Dinh, T. N., Kyaw, T. S., Kanellakis, P., To, K., Tipping, P., Toh, B.-H., Bobik, A., & Agrotis, A.
- Venue
- Circulation
- Published
- 2012-09-04
- Volume
- 126
- Issue
- 10
- Pages
- 1256-1266
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2110709781
- Cited by
- 170
- References
- 0
- FWCI
- 6.78
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.